Consensus community valuation
Hi all I am new member ,
Iam presenting valuation i have created (its Generated using Gemini Gems & brainstorming with Gemini) also using Morningstar.
Strawman Investment Report: Cochlear Limited (ASX: COH)
Date: Feb 14, 2026 | Price: $199.22 | Market Cap: ~$13.1B | Recommendation: Buy / Accumulate
1. The Result: A "Perfect Storm" of Timing & FX
Cochlear’s HY26 results triggered a violent 18.9% sell-off, with the price closing at a psychological floor of $199.22. While the headline statutory profit fell 21% (to $161.5M), the "Council" views this as an accounting mirage masking strong underlying operational health.
The Data Forensic
- Revenue: $1,176M (Up 1% reported; Down 2% in constant currency).
- Underlying NPAT: $195M (Down 9%).
- Gross Margin: 73% (Down from 75%). Management cited a "high mix of lower-tier volume" in China and "inefficient launch costs" for the Nexa system.
- Dividends: $2.15 per share (Steady). A strong signal of balance sheet health.
- Cash Position: $173M Net Cash. The business is fundamentally unshakeable.
2. The Mental Model: The "Administrative Bottleneck"
To evaluate COH at $199, we must distinguish between external demand and internal friction.
- Demand: Unit growth in Emerging Markets was +15%. In developed markets, unit growth accelerated to 10% in Nov/Dec as Nexa gained traction.
- Friction: The Nucleus Nexa rollout was delayed by hospital contracting. Cochlear sought price increases for the new tech; hospital administrators pushed back, dragging negotiations from 2 months to 5 months.
- The Model: This is a Landlord raising rent. The tenants (hospitals) complained and delayed signing, but by December, 80% of units sold were Nexa. The "rent increase" (price hike) is now locked in for the H2 harvest.
3. The Guru Scorecard: Who is doing what?
Investor
Action
The "Guru" Logic
Warren Buffett
BUY
At $199, the P/E is ~33x. Buffett loves a Wide Moat on sale. He sees the Interest Coverage (infinite due to Net Cash) as the ultimate safety net.
Aswath Damodaran
NIBBLE
His DCF (adjusted for the 73% margin) floors at $185. At $199, he finally sees a 10-15% Margin of Safety—rare for this stock.
David Gardner
HOLD
He focuses on the "Nexa" as a Rule Breaker. Upgradeable firmware is a "moat-widener." He ignores the 6-month accounting dip.
Mathan Somasundaram
WAIT
Devil’s Advocate: He worries about the $30M currency headwind and the "China Volume" trap. He'd wait for a final capitulation at $180.
Gaurav Sodhi
BUY
He loves "High Quality with a temporary blemish." He’d argue the 26% rise in Operating Cash Flow ($136M) proves the profit dip is temporary.
4. First, Second, and Third-Order Impacts
- First-Order: Passive selling. Index funds and "Quality" ETFs were forced to rebalance after the 19% drop, keeping the price suppressed.
- Second-Order: Margin recovery. As the Malaysia manufacturing site ramps up production of lower-tier units for China, the 73% margin floor will likely bounce back toward 74-75% by FY27.
- Third-Order: The "Halo Effect." If Cochlear (the most stable ASX healthcare stock) can fall 19%, the market will pre-emptively sell CSL and ResMed, creating a sector-wide value opportunity for the "Council."
5. Bull vs. Bear Summary
The Bull Case (The Council's View)
The Bear Case (The Market's Fear)
Nexa Momentum: 80% of sales are now Nexa. The H1 "delay" is just deferred revenue, not lost revenue.
Margin Compression: Gross margin fell to 73%. China's low-price tenders may be a permanent drag on ROIC.
Cash Cow: Operating Cash Flow rose 26% despite the profit drop. The business is generating more actual cash.
Adult Market Wall: Seniors are proving harder/more expensive to convert to surgery than the children's market.
Service Annuity: Each new implant in China/India locks in 70 years of high-margin processor upgrade revenue.
Currency Risk: The AUD/USD strength is a "silent killer," expected to shave $30M off the FY26 profit.
Final Valuation Verdict
Morningstar’s Fair Value of $225 assumes a recovery in H2. At $199, the market is pricing in a "Broken Growth" scenario. However, with 80% of sales already transitioned to Nexa and a steady dividend, the internal evidence suggests the "break" is purely administrative.
Strawman Conclusion: Cochlear at $199 is a rare gift for the patient investor. We are buying a 60% global monopoly at a price that assumes it has lost its pricing power—despite management confirming that price increases were successfully negotiated.
We see how the market reacts with a lower Net Profit HY26
Sales revenue up 1% (down 2% in CC*) to $1,176m
• Underlying net profit** down 9% to $195m
• Strong balance sheet with net cash of $173m
• Interim dividend steady at $2.15 per share
Underlying net profit is expected to be at the lower end of the $435-460 million guidance range provided in August 2025, reflecting the longer than anticipated contracting process for the Nexa Implant System in the first half
https://hotcopper.com.au/threads/ann-hy26-result-presentation-slides.9017437/
Return (inc div) 1yr: -18.68% 3yr: 6.57% pa 5yr: 4.95% pa
Mkt cap !
$16.10B
Operating cash flow decreased $151.2 million to $237.6 million, with free cash flow decreasing $160.7 million to $122.4 million.
https://hotcopper.com.au/threads/ann-annual-report-incl-sustainability-reporting.8712706/
The Cochlear Ltd (ASX: COH) share price is in focus today after the company reported FY25 sales revenue up 4% to $2,356 million and a 9% jump in statutory net profit to $389 million, with a 5% increase in full-year dividends.
What did Cochlear report?
- Sales revenue rose 4% to $2,356 million
- Statutory net profit up 9% to $389 million
- Underlying net profit increased 1% to $392 million, margin steady at 17%
- Final dividend of $2.15 per share, full-year dividend up 5% to $4.30 per share (72% payout)
- Cochlear implants shipped: 53,968 units, up 12%
- FY26 underlying net profit guidance: $435–460 million, up 11–17%
Return (inc div) 1yr: -8.01% 3yr: 13.44% pa 5yr: 10.23% pa
Update 15/08/2023
FY23 underlying NPAT came in at the top range of guidance finishing at $305.2m, representing a 10% increase compared to last year. Updated chart below:
FY24 outlook has been given with guidance of $355-375m underlying NPAT which would represent an increase of 16-23%.
Basing my valuation using the midpoint of this guidance ($365m) and forecasting out 5 years at 10% for years 2-5. Assuming a terminal PE of 40 gives a valuation of $202.02.
Disc: Not held.
Update 02/03/2023
Updating based on 1H FY23 results. Underlying NPAT was around $141m which was a decrease compared to PCP
Guidance for the full year for underlying NPAT was maintained at $290-$305m. Assuming full year NPAT is around $300m, then growth for the year would be around 8.35%. Below is the updated chart.
I'm gonna give them the benefit of the doubt that they can maintain 10% growth pa for the next 4 years to FY27. A PE of 40x and then discounting would give a valuation of $182.65. Still think this is too expensive for a company with slowing growth albeit in a very defensive sector.
Disc: Not held.
Update 19/08/2022
Updating based on FY22 results. Underlying NPAT came in at $277 which is in the midrange of guidance. Below is the updated chart
If I assume 12.5% growth for 5 years, a terminal PE of 40x and discount back 10% pa, then valuation comes in at around $188.70
Disc: Not Held
Original Valuation
Cochlear is one of Australia's real success stories and is the global leader in hearing implants.
Underlying net profit has been hit hard by Covid and in FY20 they also had to deal with issues in regards to a patent litigation. I have graphed out their reported underlying net profit for the last 4 years and also included an FY22 estimate of $265m which is at the low end of their guidance.
If we assume that Cochlear will be a beneficiary of a Covid reopening, and we assume a 10% increase to NPAT for the next 5 years, After discounting back 10% per annum, I have a price target of $161.34. This is assuming they are still trading at a PE of 40x in FY26.
Currently I feel the share price is a bit rich. The reported historic PE is 38.5x but this is based on the reported NPAT in FY21 of $326.5 which included $89.8m of one-off profit items related to their patent litigation. So based on their underlying NPAT they are currently trading at around 53x.
The average PE prior to FY20 was around 40x. So based on a forward PE of 40x their lower end of guidance of $265m, that gives us a share price of around $161.09. Similar to my price target as calculated above.
COH are due to report their 1H22 earnings on February 22. So I may edit my valuation based on what they report.
Disc: Not held
Cochlear announced their 1H FY22 results today. From their release:
- Sales revenue increased 10% (12% in CC) to $815m.
- Cochlear implant units increased 7% to 18,598.
- Statutory net profit of $169m includes $12m in innovation fund gains after‐tax.
- Underlying net profit increased 26% to $158m, driven by the combination of strong sales growth and improved gross margin, with some benefit from lower‐than‐expected operating expenses.
- The interim dividend increased 35% to $1.55 per share, representing a payout of 65% of underlying net profit. We expect the dividend payout to be around 70% for the full year, in line with our target payout.
- FY22 underlying net profit guidance range maintained at $265‐285m, a 13‐22% increase on underlying net profit for FY21. Guidance now incorporates cloud computing expenses and anticipates continuing COVID impacts for the balance of the year. A more material disruption from COVID than experienced in the first half remains a risk factor that does not form part of guidance.
Overall I think this is a pretty good result given the continued covid headwinds it is facing. Guidance was reaffirmed so perhaps they are expecting a weaker 2H?
See my valuation for more details.
I still think it is quite expensive, especially after the jump after results were released. At the current price it is around 50x the mid range ($275m) of their guided underlying NPAT.
Disc: Not held